Company Overview and News

0
India Glycols Limited - Updates

4h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Updates

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Shareholders meeting

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Date of payment of dividend

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Raising of Funds

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - AGM/Book Closure

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
10th Edition of MANUFACTURING IT SUMMIT to be Held on June 14th

2018-05-25 freepressjournal.in
The Indian manufacturing sector is sprinting at a never before pace fueled by the dynamic technological innovations and a growing number of organizations are proactively adapting these emerging advancements. The manufacturing companies are moving swiftly from mass production to customized production using technology and digital platforms. What’s important to note is that, this is just one among many transformations the industry is concurring due to adaptive advancements in IT, for manufacturing.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

0
10th Edition of manufacturing IT summit to be held on June 14

2018-05-25 freepressjournal.in
The 10th edition manufacturing IT summit will be held on June 14 in Mumbai. The summit is the perfect platform for C-suite executives of manufacturing companies across industries, to come together and discuss the IT trends in Indian manufacturing industry, network with peers, and build ROI-backed business relations. This summit also facilitates a marketplace for the buyers to meet with the sellers offering disruptive solutions on the emerging trends in manufacturing’s IT.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

0
Manufacturing IT summit: A call for manufacturers

2018-05-23 freepressjournal.in
The Indian manufacturing sector is sprinting at a never before pace. It is fuelled by the dynamic technological innovations and a growing number of organisations that are proactively adapting these emerging advancements. The 10th edition of manufacturing IT summit which is the perfect platform for C-suite executives of manufacturing companies across industries, will take place in June 14, 2018. The executives will come together and discuss the IT trends in Indian manufacturing industry, network with peers, and build ROI-backed business relations.
GABRIEL INDIAGLYCO AUROPHARMA 524804 ARBQY MINDAIND 505714 500201 532539

0
India Glycols Limited - Raising of Funds

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Dividend

2018-05-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Outcome of Board Meeting

2018-05-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Dividend

2018-05-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

0
India Glycols Limited - Outcome of Board Meeting

2018-05-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIAGLYCO 500201

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...